Eliza Slawther
Senior Writer
Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
EU: ‘Urgent Action’ Needed From Industry & Member States To Curb GLP-1 Shortages
The off-label “cosmetic” use of GLP-1 receptor agonists such as Ozempic and Wegovy is contributing to global shortages of these drugs, prompting the European Medicines Agency to ask member states and manufacturers to “control and optimize” their use.
EU Cross-Border Access Laws Present ‘Unique Challenges’ For ATMPs
EU citizens can access medical treatments in countries other than their own through cross-border health care regulations – but these legislations were not built with advanced therapy medicinal products (ATMPs) in mind, experts warn.
England’s NICE Not Planning To Include Societal & Genericization Factors In HTAs – For Now
England’s NICE should factor in the impact of patent expiry on future drug prices when analyzing the cost effectiveness of new medicines and should also take account of societal benefits, a group of health economists has said.
England's NICE Backs Vertex’s CF Drugs Kaftrio, Symkevi & Orkambi After Initial Rejection
Cystic fibrosis patients in England will be able to access Vertex’s three combination therapies after the company announced an extended reimbursement agreement with the National Health Service and a positive opinion from the country’s HTA body, NICE.
Global Governments ‘Neglecting’ Vaccine Investment Post-COVID
Seth Berkley, epidemiologist and former CEO of Gavi, the vaccine alliance, has emphasized the importance of making “investments in peacetime” to prepare for pandemic threats and called for a “mindset change” among global governments.
EU HTA Regulation: Guidance Released On Joint Clinical Assessment Scoping & Reporting
The European Commission’s Member State Coordination Group on HTA has released two new guidance documents aimed at helping member states and assessors to navigate joint clinical assessments under the Health Technology Assessment Regulation.